{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:03:01Z","timestamp":1788188581337,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"45","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974425"],"award-info":[{"award-number":["81974425"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772911"],"award-info":[{"award-number":["81772911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903648"],"award-info":[{"award-number":["81903648"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010014","name":"Six Talent Peaks Project in Jiangsu Province","doi-asserted-by":"publisher","award":["SWYY-095"],"award-info":[{"award-number":["SWYY-095"]}],"id":[{"id":"10.13039\/501100010014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20170744"],"award-info":[{"award-number":["BK20170744"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M652035"],"award-info":[{"award-number":["2019M652035"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,11,5]]},"DOI":"10.1038\/s41388-020-01474-x","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T11:04:17Z","timestamp":1601031857000},"page":"6893-6905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1\u03b1 mediated XPC transcription"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-679X","authenticated-orcid":false,"given":"Yunyao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-7093","authenticated-orcid":false,"given":"Xiaosheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1576-8787","authenticated-orcid":false,"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-3164","authenticated-orcid":false,"given":"Lei","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"1474_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1474_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.critrevonc.2015.11.019","volume":"99","author":"C Deben","year":"2016","unstructured":"Deben C, Deschoolmeester V, Lardon F, Rolfo C, Pauwels P. TP53 and MDM2 genetic alterations in non-small cell lung cancer: evaluating their prognostic and predictive value. Crit Rev Oncol Hematol. 2016;99:63\u201373.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1474_CR3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr., Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299\u2013311.","journal-title":"Lancet"},{"key":"1474_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.lungcan.2010.08.022","volume":"71","author":"A Chang","year":"2011","unstructured":"Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71:3\u201310.","journal-title":"Lung Cancer"},{"key":"1474_CR5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0305-7372(03)00003-3","volume":"29","author":"AM Shannon","year":"2003","unstructured":"Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29:297\u2013307.","journal-title":"Cancer Treat Rev"},{"key":"1474_CR6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00280-006-0224-7","volume":"58","author":"X Song","year":"2006","unstructured":"Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharm. 2006;58:776\u201384.","journal-title":"Cancer Chemother Pharm"},{"key":"1474_CR7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","volume":"26","author":"P Vaupel","year":"2007","unstructured":"Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225\u201339.","journal-title":"Cancer Metastasis Rev"},{"key":"1474_CR8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2011.03.014","volume":"308","author":"C Wohlkoenig","year":"2011","unstructured":"Wohlkoenig C, Leithner K, Deutsch A, Hrzenjak A, Olschewski A, Olschewski H. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. Cancer Lett. 2011;308:134\u201343.","journal-title":"Cancer Lett"},{"key":"1474_CR9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","volume":"29","author":"GL Semenza","year":"2010","unstructured":"Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29:625\u201334.","journal-title":"Oncogene"},{"key":"1474_CR10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/mol.105.015743","volume":"69","author":"LM Brown","year":"2006","unstructured":"Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharm. 2006;69:411\u20138.","journal-title":"Mol Pharm"},{"key":"1474_CR11","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-8-1","volume":"8","author":"L Nardinocchi","year":"2009","unstructured":"Nardinocchi L, Puca R, Sacchi A, D\u2019Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer. 2009;8:1.","journal-title":"Mol Cancer"},{"key":"1474_CR12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/cam4.991","volume":"6","author":"T Sowa","year":"2017","unstructured":"Sowa T, Menju T, Chen-Yoshikawa TF, Takahashi K, Nishikawa S, Nakanishi T, et al. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Cancer Med. 2017;6:288\u201397.","journal-title":"Cancer Med"},{"key":"1474_CR13","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1158\/0008-5472.CAN-09-1770","volume":"69","author":"AM Roberts","year":"2009","unstructured":"Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res. 2009;69:9056\u201364.","journal-title":"Cancer Res"},{"key":"1474_CR14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11596-016-1586-7","volume":"36","author":"SL Yang","year":"2016","unstructured":"Yang SL, Ren QG, Wen L, Hu JL. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis. J Huazhong Univ Sci Technol Med Sci. 2016;36:321\u20137.","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"1474_CR15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/JTO.0b013e31819852d5","volume":"4","author":"T Yohena","year":"2009","unstructured":"Yohena T, Yoshino I, Takenaka T, Kameyama T, Ohba T, Kuniyoshi Y, et al. Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol. 2009;4:284\u201390.","journal-title":"J Thorac Oncol"},{"key":"1474_CR16","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1073\/pnas.1001296107","volume":"107","author":"J Mazumdar","year":"2010","unstructured":"Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, et al. HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci USA. 2010;107:14182\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1474_CR17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.molcel.2010.10.030","volume":"40","author":"H Cam","year":"2010","unstructured":"Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. Mol Cell. 2010;40:509\u201320.","journal-title":"Mol Cell"},{"key":"1474_CR18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.molcel.2013.10.019","volume":"52","author":"MM Olcina","year":"2013","unstructured":"Olcina MM, Foskolou IP, Anbalagan S, Senra JM, Pires IM, Jiang Y, et al. Replication stress and chromatin context link ATM activation to a role in DNA replication. Mol Cell. 2013;52:758\u201366.","journal-title":"Mol Cell"},{"key":"1474_CR19","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/carcin\/bgn231","volume":"29","author":"R Wirthner","year":"2008","unstructured":"Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts. Carcinogenesis. 2008;29:2306\u201316.","journal-title":"Carcinogenesis"},{"key":"1474_CR20","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1038\/sj.emboj.7601369","volume":"25","author":"KK To","year":"2006","unstructured":"To KK, Sedelnikova OA, Samons M, Bonner WM, Huang LE. The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J. 2006;25:4784\u201394.","journal-title":"EMBO J"},{"key":"1474_CR21","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/cr068207j","volume":"107","author":"Y Jung","year":"2007","unstructured":"Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev. 2007;107:1387\u2013407.","journal-title":"Chem Rev"},{"key":"1474_CR22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1101\/sqb.2000.65.173","volume":"65","author":"RD Wood","year":"2000","unstructured":"Wood RD, Araujo SJ, Ariza RR, Batty DP, Biggerstaff M, Evans E, et al. DNA damage recognition and nucleotide excision repair in mammalian cells. Cold Spring Harb Symp Quant Biol. 2000;65:173\u201382.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"1474_CR23","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/onc.2011.189","volume":"30","author":"RY Liu","year":"2011","unstructured":"Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu X, et al. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene. 2011;30:4814\u201323.","journal-title":"Oncogene"},{"key":"1474_CR24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14:1291\u20135.","journal-title":"Clin Cancer Res"},{"key":"1474_CR25","first-page":"4899","volume":"62","author":"T Furuta","year":"2002","unstructured":"Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62:4899\u2013902.","journal-title":"Cancer Res"},{"key":"1474_CR26","first-page":"1311","volume":"63","author":"M Selvakumaran","year":"2003","unstructured":"Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63:1311\u20136.","journal-title":"Cancer Res"},{"key":"1474_CR27","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869\u201383.","journal-title":"Oncogene"},{"key":"1474_CR28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2018.00290","volume":"8","author":"LB Hu","year":"2018","unstructured":"Hu LB, Chen Y, Meng XD, Yu P, He X, Li J. Nucleotide excision repair factor XPC ameliorates prognosis by increasing the susceptibility of human colorectal cancer to chemotherapy and ionizing radiation. Front Oncol. 2018;8:290.","journal-title":"Front Oncol"},{"key":"1474_CR29","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1093\/nar\/gky764","volume":"46","author":"J Slyskova","year":"2018","unstructured":"Slyskova J, Sabatella M, Ribeiro-Silva C, Stok C, Theil AF, Vermeulen W, et al. Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage. Nucleic Acids Res. 2018;46:9537\u201349.","journal-title":"Nucleic Acids Res"},{"key":"1474_CR30","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7150\/jca.25814","volume":"10","author":"X Xie","year":"2019","unstructured":"Xie X, Huang N, Zhang Y, Wei X, Gao M, Li M, et al. MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901\/DDP cells. J Cancer. 2019;10:1039\u201351.","journal-title":"J Cancer"},{"key":"1474_CR31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3892\/etm.2016.3320","volume":"12","author":"JY Lee","year":"2016","unstructured":"Lee JY, Park W. Anti-inflammatory effects of oroxylin A on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid. Exp Ther Med. 2016;12:151\u20136.","journal-title":"Exp Ther Med"},{"key":"1474_CR32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fonc.2019.00188","volume":"9","author":"H Cao","year":"2019","unstructured":"Cao H, Li W, Zhou Y, Tan R, Yang Y, Zhou Y, et al. Oroxylin a inhibits the protection of bone marrow microenvironment on CML cells through CXCL12\/CXCR4\/P-gp signaling pathway. Front Oncol. 2019;9:188.","journal-title":"Front Oncol"},{"key":"1474_CR33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.biopha.2017.10.140","volume":"97","author":"J Jin","year":"2018","unstructured":"Jin J, Chen S, Wang D, Chen Y, Wang Y, Guo M, et al. Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs. Biomed Pharmacother. 2018;97:385\u201394.","journal-title":"Biomed Pharmacother"},{"key":"1474_CR34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mc.22540","volume":"56","author":"W Li","year":"2017","unstructured":"Li W, Ding Q, Ding Y, Lu L, Wang X, Zhang Y, et al. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12\/CXCR7 axis in bone marrow microenvironment. Mol Carcinog. 2017;56:863\u201376.","journal-title":"Mol Carcinog"},{"key":"1474_CR35","doi-asserted-by":"crossref","first-page":"17392","DOI":"10.1002\/jcp.28361","volume":"234","author":"M Wei","year":"2019","unstructured":"Wei M, Ma R, Huang S, Liao Y, Ding Y, Li Z, et al. Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1alpha\/hedgehog pathway under hypoxia. J Cell Physiol. 2019;234:17392\u2013404.","journal-title":"J Cell Physiol"},{"key":"1474_CR36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.toxlet.2013.01.019","volume":"219","author":"L Zhu","year":"2013","unstructured":"Zhu L, Zhao L, Wang H, Wang Y, Pan D, Yao J, et al. Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7\/ADR cells by G2\/M arrest. Toxicol Lett. 2013;219:107\u201315.","journal-title":"Toxicol Lett"},{"key":"1474_CR37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1139\/o2012-005","volume":"90","author":"J Ha","year":"2012","unstructured":"Ha J, Zhao L, Zhao Q, Yao J, Zhu BB, Lu N, et al. Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway. Biochem Cell Biol. 2012;90:521\u201331.","journal-title":"Biochem Cell Biol"},{"key":"1474_CR38","doi-asserted-by":"crossref","first-page":"8547846","DOI":"10.1155\/2019\/8547846","volume":"2019","author":"MA Akanji","year":"2019","unstructured":"Akanji MA, Rotimi D, Adeyemi OS. Hypoxia-inducible factors as an alternative source of treatment strategy for cancer. Oxid Med Cell Longev. 2019;2019:8547846.","journal-title":"Oxid Med Cell Longev"},{"key":"1474_CR39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cca.2008.05.002","volume":"395","author":"S Kaluz","year":"2008","unstructured":"Kaluz S, Kaluzova M, Stanbridge EJ. Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clin Chim Acta. 2008;395:6\u201313.","journal-title":"Clin Chim Acta"},{"key":"1474_CR40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/carcin\/bgs142","volume":"33","author":"Y Liu","year":"2012","unstructured":"Liu Y, Bernauer AM, Yingling CM, Belinsky SA. HIF1alpha regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis. 2012;33:1187\u201392.","journal-title":"Carcinogenesis"},{"key":"1474_CR41","first-page":"1243","volume":"25","author":"TC Lai","year":"2011","unstructured":"Lai TC, Chow KC, Fang HY, Cho HC, Chen CY, Lin TY, et al. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients. Oncol Rep. 2011;25:1243\u201351.","journal-title":"Oncol Rep."},{"key":"1474_CR42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mc.20789","volume":"51","author":"HY Yang","year":"2012","unstructured":"Yang HY, Zhao L, Yang Z, Zhao Q, Qiang L, Ha J, et al. Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402\/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kappaB signaling pathway. Mol Carcinog. 2012;51:185\u201395.","journal-title":"Mol Carcinog"},{"key":"1474_CR43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.taap.2012.01.019","volume":"259","author":"B Zhu","year":"2012","unstructured":"Zhu B, Zhao L, Zhu L, Wang H, Sha Y, Yao J, et al. Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinbeta1 and its related pathway. Toxicol Appl Pharm. 2012;259:387\u201394.","journal-title":"Toxicol Appl Pharm"},{"key":"1474_CR44","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/ptr.5694","volume":"30","author":"L Lu","year":"2016","unstructured":"Lu L, Guo Q, Zhao L. Overview of Oroxylin A: a promising flavonoid compound. Phytother Res. 2016;30:1765\u201374.","journal-title":"Phytother Res"},{"key":"1474_CR45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud GN, Li W. HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378\u201389.","journal-title":"Acta Pharm Sin B"},{"key":"1474_CR46","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","volume":"294","author":"RK Bruick","year":"2001","unstructured":"Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337\u201340.","journal-title":"Science"},{"key":"1474_CR47","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3346\/jkms.2002.17.5.581","volume":"17","author":"YS Chun","year":"2002","unstructured":"Chun YS, Kim MS, Park JW. Oxygen-dependent and -independent regulation of HIF-1alpha. J Korean Med Sci. 2002;17:581\u20138.","journal-title":"J Korean Med Sci"},{"key":"1474_CR48","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1021\/acs.jmedchem.8b01596","volume":"62","author":"Z Li","year":"2019","unstructured":"Li Z, You Q, Zhang X. Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications. J Med Chem. 2019;62:5725\u201349.","journal-title":"J Med Chem"},{"key":"1474_CR49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","volume":"33","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharm Sci. 2012;33:207\u201314.","journal-title":"Trends Pharm Sci"},{"key":"1474_CR50","doi-asserted-by":"crossref","first-page":"9266","DOI":"10.1021\/acs.jmedchem.8b00971","volume":"61","author":"H An","year":"2018","unstructured":"An H, Lee S, Lee JM, Jo DH, Kim J, Jeong YS, et al. Novel hypoxia-inducible factor 1alpha (HIF-1alpha) inhibitors for angiogenesis-related ocular diseases: discovery of a novel scaffold via ring-truncation strategy. J Med Chem. 2018;61:9266\u201386.","journal-title":"J Med Chem"},{"key":"1474_CR51","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1021\/acs.jmedchem.5b01220","volume":"58","author":"DY Kwon","year":"2015","unstructured":"Kwon DY, Lee HE, Weitzel DH, Park K, Lee SH, Lee CT, et al. Synthesis and biological evaluation of manassantin analogues for hypoxia-inducible factor 1alpha inhibition. J Med Chem. 2015;58:7659\u201371.","journal-title":"J Med Chem"},{"key":"1474_CR52","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1021\/jm0610292","volume":"50","author":"K Lee","year":"2007","unstructured":"Lee K, Lee JH, Boovanahalli SK, Jin Y, Lee M, Jin X. et al. (Aryloxyacetylamino)benzoic acid analogues: a new class of hypoxia-inducible factor-1 inhibitors. J Med Chem. 2007;50:1675\u201384.","journal-title":"J Med Chem"},{"key":"1474_CR53","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1021\/jm301419d","volume":"55","author":"R Naik","year":"2012","unstructured":"Naik R, Won M, Kim BK, Xia Y, Choi HK, Jin G, et al. Synthesis and structure-activity relationship of (E)-phenoxyacrylic amide derivatives as hypoxia-inducible factor (HIF) 1alpha inhibitors. J Med Chem. 2012;55:10564\u201371.","journal-title":"J Med Chem"},{"key":"1474_CR54","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1038\/sj.onc.1206666","volume":"22","author":"S Kothari","year":"2003","unstructured":"Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene. 2003;22:4734\u201344.","journal-title":"Oncogene"},{"key":"1474_CR55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2005.05.028","volume":"237","author":"J Zhou","year":"2006","unstructured":"Zhou J, Schmid T, Schnitzer S, Brune B. Tumor hypoxia and cancer progression. Cancer Lett. 2006;237:10\u201321.","journal-title":"Cancer Lett"},{"key":"1474_CR56","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1159\/000489418","volume":"46","author":"YB Liu","year":"2018","unstructured":"Liu YB, Mei Y, Tian ZW, Long J, Luo CH, Zhou HH. Downregulation of RIF1 enhances sensitivity to platinum-based chemotherapy in epithelial ovarian cancer (EOC) by regulating nucleotide excision repair (NER) pathway. Cell Physiol Biochem. 2018;46:1971\u201384.","journal-title":"Cell Physiol Biochem"},{"key":"1474_CR57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/15548627.2015.1110667","volume":"12","author":"L Qiang","year":"2016","unstructured":"Qiang L, Zhao B, Shah P, Sample A, Yang S, He YY. Autophagy positively regulates DNA damage recognition by nucleotide excision repair. Autophagy. 2016;12:357\u201368.","journal-title":"Autophagy"},{"key":"1474_CR58","first-page":"1875","volume":"41","author":"X Teng","year":"2019","unstructured":"Teng X, Fan XF, Li Q, Liu S, Wu DY, Wang SY, et al. XPC inhibition rescues cisplatin resistance via the Akt\/mTOR signaling pathway in A549\/DDP lung adenocarcinoma cells. Oncol Rep. 2019;41:1875\u201382.","journal-title":"Oncol Rep"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01474-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T19:15:14Z","timestamp":1632510914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01474-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":58,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2020,11,5]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-01474-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}